Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RBP-7000 in Stable Schizophrenia
NCT02765555Phase 1Completed
- Sponsor
- Indivior
- Start
- Mar 2010
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Indivior. Primary endpoints: Incidence of treatment emergent adverse and serious adverse events, Maximum plasma concentration and 7 more. Started Mar 2010; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02765555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765555.